Pure Global AI
NCT06255964Not yet recruiting

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

A Phase I/II Clincal Trial of Intravesical IAP0971 in Combination With Bacillus Calmette Guerin (BCG) in Patients With BCG Unresponsive High Risk Non-Muscular Invasive Bladder Cancer (NMIBC)
SUNHO（China）BioPharmaceutical CO., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Bladder Cancer
Drug/Device/Intervention
IAP0971
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
SUNHO（China）BioPharmaceutical CO., Ltd.
Timeline & enrollment
Phase
Phase 1/2
Start date
Feb 15, 2024
End date
Dec 07, 2026
Enrollment
236 participants
Primary outcome

DLTs occurrence

Summary

The efficacy and safety of IAP0971 single drug or combined with BCG intravesical instillation
 in the treatment of high-risk non muscle invasive bladder cancer with BCG treatment failure.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06255964
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06255964 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by SUNHO（China）BioPharmaceutical CO., Ltd. and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 236 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.